The significance of immunohistochemically detectable tumor cells in lymph nodes;Die rolle von immunhistochemisch detektierbaren tumorzellen in lymphknoten

Zentralblatt fur Chirurgie

Volumn 125, Issue 10, 2000, Pages 796-798

  Izbicki, J R ^a   Hosch, S B ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Epithelial tumors; Minimal lymphatic tumor cell dissemination; Minimal residual disease; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; DRUG TARGETING; EFFECTOR CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PROGNOSIS; TUMOR CELL;

EID: 0033735793     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-10048     Document Type: Article

References (16)

1. Monitoring of reduction of 17-1A-expressing breast cancer micrometastases during antibody therapy with edrecolomab - A pilot study
2. Isolated CEA/CA19-9 rise in pretreated colon carcinoma patients stage Dukes B and C: A new approach to murine 17-1A antibody-therapy
3. An overview of adjuvant therapy for colorectal cancer
4. Early lymphatic tumor cell dissemination in pancreatic cancer: Frequency and prognostic significance
5. Cryptic tumor cells in lymph nodes of patients with esophageal cancer
6. Prognostic significance of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer
7. Micrometastases and survival in stage II colorectal cancer
8. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
9. Micrometastasis detection and treatment with monoclonal antibodies
10. Differential expression of proliferation associated molecules in individual micrometastatic carcinoma cells
11. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer
12. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
13. Tumorigenic potential of apparently tumor-free lymph nodes
14. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
15. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours
16. Open label pilot study of monoclonal antibody 17-1A in combination with 5-Fluorouracil/Levamisol or 5-FU/Folinic acid in patients with advanced colorectal cancer